Edelweiss has come out with its first quarter (April-June) earnings estimates for the pharmaceuticals sector. The brokerage house expects Cipla to report a 522.4 percent growth quarter-on-quarter (degrowth of 22.6 percent year-on-year) in net profit at Rs 503.3 crore.
Net Sales are expected to increase by 21.7 percent Q-o-Q (up 3.2 percent Y-o-Y) to Rs 3976.4 crore, according to Edelweiss.
Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to rise by 259.1 percent Q-o-Q (down 24.3 percent Y-o-Y) to Rs 786.2 crore.
Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
